Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (4472)	6/12/1998 12:13:00 PM
From: Steve Fancy	of 6136

RESEARCH ALERT - Agouron (NASDAQ:AGPH) raised to buy Reuters, Friday, June 12, 1998 at 12:06 NEW YORK, June 12 (Reuters) - BT Alex. Brown analysts Kevin Tang and Patrick Cheng raised their rating for Agouron Pharmaceuticals Inc. Friday to buy from market perform. -- In a report, they said a deal between Agouron and Immune Response Corp. (NASDAQ:IMNR) would help Agouron. The agreement calls for collaboration on developing and commercializing Remune, Immune Response's drug for HIV infection. -- "We believe that Agouron negotiated a deal that represents a good risk/reward profile for its shareholders." -- They set a new 12-month price target of $48 for the stock. Agouron was up 3/16 to 33-15/16 and Immune Response fell 8/16 to 13-3/16. Copyright 1998, Reuters News Service Companies o

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next